The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Simaniv T.O.

Neurology Research Center, Moscow

Ivanova M.V.

FGBU "Nauchnyĭ tsentr nevrologii" RAMN, Moskva

Briukhov V.V.

Zakharova M.N.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

A case of subtentorial progressive multifocal leucoencephalopathy in a patient treated with natalizumab

Authors:

Simaniv T.O., Ivanova M.V., Briukhov V.V., Zakharova M.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2‑2): 98‑106

DOI: 10.17116/jnevro20191192298

Read: 1485 times

Download PDF (RU)
Contact the author
Table of contents

A CASE OF SUBTENTORIAL PROGRESSIVE MULTIFOCAL LEUCOENCEPHALOPATHY IN A PATIENT TREATED WITH NATALIZUMAB
A CASE OF SUBTENTORIAL PROGRESSIVE MULTIFOCAL LEUCOENCEPHALOPATHY IN A PATIENT TREATED WITH NATALIZUMAB

To cite this article:

Simaniv TO, Ivanova MV, Briukhov VV, Zakharova MN. A case of subtentorial progressive multifocal leucoencephalopathy in a patient treated with natalizumab. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2‑2):98‑106. (In Russ.)
https://doi.org/10.17116/jnevro20191192298

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Quantitative analysis of cere­brospinal fluid flow in multiple scle­rosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):45-50
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Abstract:

This paper presents a case report of subtentorial progressive multifocal leukoencephalopathy (PML) in a 26-year-old female patient treated with natalizumab. The evolution of clinical features, neuroimaging data and treatment as well as the development of immune reconstitution inflammatory syndrome (IRIS) are described. This case emphasizes the importance to keep accurately the risk management plan during natalizumab treatment. This includes performing MRI scans in order to detect changes typical for PML at the earliest (preclinical) stage in time.

Keywords:

multiple sclerosis
natalizumab
monoclonal antibodies
progressive multifocal leukoencephalopathy (PML)
JC-virus
immune reconstitution inflammatory syndrome (IRIS)

Authors:

Simaniv T.O.

Neurology Research Center, Moscow

Ivanova M.V.

FGBU "Nauchnyĭ tsentr nevrologii" RAMN, Moskva

Briukhov V.V.

Zakharova M.N.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Close metadata

References:

  1. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor B V. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022-1024. https://doi.org/10.1212/WNL.0000000000000768
  2. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016;172(1):3-13. https://doi.org/10.1016/j.neurol.2015.10.006
  3. Brandstadter R, Sand IK. The use of natalizumab for multiple sclerosis. Neuropsychiatr Dis Treat. 2017;13:1691. https://doi.org/10.2147/NDT.S114636
  4. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254-260. https://doi.org/10.1016/S1474-4422(09)70021-3
  5. Vorobyeva AA, Simaniv TO, Zakharova MN, Zavalishin IA, Peresedova AV Experience of Using Natalizumab (Tysabri) at the Research Center of Neurology. Effective Pharmacotherapy. 2014;58(6):4-11. (In Russ.)
  6. Prosperini L, Fanelli F, Pozzilli C. Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis. J Neurol Sci. 2016;364:145-147. https://doi.org/10.1016/j.jns.2016.03.025
  7. Popova EV, Brylev LV, Davydovskaia MV. Natalizumab in the treatment of patients with relapsing-remitting multiple sclerosis: the preliminary results of the observational program «Sovet». Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2013;113(2-2):79-82. (In Russ.)
  8. Davydovskaya MV, Khachanova NV, Evdoshenko EP, Pronin IN, Boiko AN, Zakharova MN, Alifirova VM, Turova EA, Malkova NA, Sivertseva SA, Tsukurova LA, Skoromets AA, Solodun IYu. Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(10):77. (In Russ.) https://doi.org/10.17116/jnevro201611610279-97
  9. O’connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 2014;83(1):78-86. https://doi.org/10.1212/WNL.0000000000000541
  10. Zakharova MN. Progressive multifocal leukoencephalopathy (review). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(9-2):29-33. (In Russ.)
  11. Williamson EML, Berger JR. Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics. 2017;14:1-13. https://doi.org/10.1007/s13311-017-0570-7
  12. Knowles WA Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol. 2006;577:19-45. https://doi.org/10.1007/0-387-32957-9_2
  13. Zakharova MN, Lysogorskaia EV, Trushnikova TN, Zhelnin AV. The case-report of progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(8-2):107-109. (In Russ.) https://doi.org/10.17116/jnevro2018118082107
  14. European Medicines Agency. EMA confirms recommendations to minimise risk of brain infection PML with Tysabri. London. 2016.
  15. Kulikova SN, Briukhov VV, Peresedova AV, Krotenkova MV, Zavalishin IA. MRI-diagnosis of progressive multifocal leukoencephalopathy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2013;113(10):95-101. (In Russ.)
  16. Post MJ, Yiannoutsos C, Simpson D, Booss J, Clifford DB, Cohen B, McArthur JC, Hall CD. Progressive multifocal encephalopathy in AIDS: are there any MR-findings useful to patient management and predictive of patient survival? AIDS clinical trials group 243 Team. Am J Neuroradiol. 1999;20(10):1896-1906.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.